Form 8-K - Current report:
SEC Accession No. 0001493152-26-028457
Filing Date
2026-06-12
Accepted
2026-06-12 16:30:27
Documents
12
Period of Report
2026-06-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41045
2 EX-3.1 ex3-1.htm EX-3.1 10311
  Complete submission text file 0001493152-26-028457.txt   221248

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gtbp-20260608.xsd EX-101.SCH 3023
4 XBRL LABEL FILE gtbp-20260608_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE gtbp-20260608_pre.xml EX-101.PRE 22364
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3326
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 261087248
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)